Mdm2 affects genome stability independent of p53

Cancer Research

Volumn 69, Issue 5, 2009, Pages 1697-1701

  Bouska, Alyssa ^a   Eischen, Christine M ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; MRE11 PROTEIN; NIBRIN; PROTEIN MDM2; PROTEIN P53; RAD50 PROTEIN; CELL CYCLE PROTEIN; NBN PROTEIN, HUMAN; NUCLEAR PROTEIN;

DOUBLE STRANDED DNA BREAK; GENETIC TRANSFORMATION; GENOMIC INSTABILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; ANIMAL; CELL TRANSFORMATION; DNA REPAIR; GENETICS; NEOPLASM; PHYSIOLOGY;

ANIMALS; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62449215026     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3732     Document Type: Review

References (27)

1. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006;13:927-934
2. Hollstein M, Bice K, Greehblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-3555
3. Sherr CJ. Divorcing ARF and p53: an unsettledase. Nat Rev Cancer 2006;6:663-673
4. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998:26: 3453-3459
5. Watanabe T, Ichikawa A, Salto H, Hotta T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma 1996;21:391-397
6. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007;26:1317-1323
7. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 1998;95:15608-15612
8. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 2003;22:1442-1450
9. Mendrysa SM, O'Leary KA, McElwee MK, et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 2006;20:16-21.
10. Wang P, Greiner TC, Lushnikova T, Eischen CM. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF. Oncogene 2006;25: 3708-3718
11. Ganguli G, Wasyiyk B. p53-independent functions of MDM2. MoI Cancer Res 2003;1:1027-1035
12. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799
13. Lu ML, Wikman F, Orntoft TF, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002;8:171-179
14. McDonnell TJ, Montes de Oca Luna R, Cho S, Ameise LL, Chavez-Reyes A, Lozano G. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol 1999;188:322-328
15. Lundgren K, Montes de Oca Luna R, McNeill YB, et al. Targeted expression of MDM2 uncouples S phase from mitosis and Inhibits mammary gland development independent of p53. Genes Dev 1997;11:714-725
16. Harris LC. MDM2 splice variants and their therapeutic implications. Curr Cancer Drug Targets 2005;5:21-26
17. Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, Eischen CM. Mdm2 binds to Nbsl at sites of DNA damage and regulates double strand break repair. J Biol Chem 2005;280:18771-18781
18. Stracker TH, Theunissen JW, Morales M, Petřini JH. The Mrell complex and the metabolism of chromosome breaks: the importance of communicating and holding things together. DNA Repair (Amst) 2004;3:845-854
19. Bouska A, Lushnikova T, Plaza S, Eischen CM. Mdm2 promotes genetic instability and transformation independent of p53. MoI CeU Biol 2008;28:4862-4874
20. Carroll PE, Okuda M, Horn HF, et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999;18:1935-1944.
21. Wang P, Lushnikova T, Odvody J, Greiner TC, Jones SN, Eischen CM. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 2008;27:1590-1598
22. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sei 2006;31:402-410
23. de Toledo SM, Azzam EI, Dahlberg WK, Gooding TB, Little JB. ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human, cells exposed to ionizing radiation. Oncogene 2000;19:6185-6193
24. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008;18:134-147
25. Rahal EA, Henricksen LA, Li Y, Turchi JJ, Pawelczak KS, Dixon K. ATM mediates repression of DNA enddegradation in an ATP-dependent manner. DNA Repair (Amst) 2008:7:464-475
26. Batchelor E, Mock CS, Bhan I, Loewer A, Lahav G. Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage. MoI Cell 2008:30: 277-289
27. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends MoI Med 2007:13:23-31.